Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.

@article{Saravolatz1996ZidovudineAO,
title={Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.},
author={Louis D. Saravolatz and Dean L. Winslow and Gary Collins and James S. Hodges and Carla Pettinelli and Daniel S. Stein and Norman Markowitz and Randall R. Reves and Mark O. Loveless and Lawrence John Crane and Melanie R. Thompson and Donald A. Abrams},
journal={The New England journal of medicine},
year={1996},
volume={335 15},
pages={
1099-106
}
}

BACKGROUND
We compared two combinations of nucleosides with zidovudine alone in patients with advanced human immunodeficiency virus (HIV) infection.
METHODS
A total of 1102 patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter were randomly assigned to receive zidovudine alone or zidovudine combined with either didanosine or zalcitabine. Disease progression, survival, toxic effects, and the CD4 cell response were assessed.
RESULTS
After a… CONTINUE READING